TA-HPV
AXP000190.1 · Cancer vaccine
- Platform
- vaccinia virus
- Originator
- Cantab Pharmaceuticals
Names
| Name | Type | Source |
|---|---|---|
| TA-HPV | preferred name, code | curator, ncit |
| Human Papillomavirus Tumor Antigen Vaccine | synonym | ncit |
Virus
- Role
- Vaccine vector
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Replication
- replicating
- Modifications
- HPV-16 and HPV-18 E6/E7 cassettes inserted into vaccinia
- Transgenes
- HPV-16 E6, HPV-16 E7, HPV-18 E6, HPV-18 E7
- Source
- evidence
Cross-references
- NCI Thesaurus
- C2403
Approvals
No regulatory approval recorded.
Clinical trials (4)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06315257 | A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients | Recruiting | Phase 1 | 2025-07-23 | 2029-06 | 32 | Cervical Cancer |
| NCT06508138 | Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection | Enrolling by invitation | Phase 1 | 2023-10-18 | 2027-04-18 | 24 | HPV 16 Infection; HPV-Related Carcinoma; Metastatic Cancer; Recurrence |
| NCT05799144 | pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer | Recruiting | Phase 2 | 2023-07-26 | 2027-09-30 | 54 | Metastatic Oropharyngeal Carcinoma; Recurrent Oropharyngeal Carcinoma |
| NCT00788164 | Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia | Completed | Phase 1 | 2008-11 | 2023-08 | 75 | Cervical Cancer; HPV Disease; Human Papilomavirus; Precancerous Condition |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 33468698 | Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody. | mBio | 2021 | cited by trial NCT00788164 |
| PMID 26420854 | Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2016 | cited by trial NCT00788164 |
| PMID 24477000 | Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. | Science translational medicine | 2014 | cited by trial NCT00788164 |
| PMID 16803488 | Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2006 | name in abstract: TA-HPV |
| PMID 15246603 | Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). | Vaccine | 2004 | name in title: TA-HPV |
| PMID 14614000 | Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2003 | name in abstract: TA-HPV |
| PMID 8684105 | A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. | Lancet (London, England) | 1996 | name in abstract: TA-HPV |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 30296681 | Epithelial boost enhances antigen expression by vaccinia virus for the generation of potent CD8+ T cell-mediated antitumor immunity following DNA priming vaccination. | Virology | 2018 | name in abstract: TA-HPV |
| PMID 23615841 | Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. | Cancer immunology, immunotherapy : CII | 2013 | name in abstract: TA-HPV |
| PMID 20886392 | TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases. | Current opinion in molecular therapeutics | 2010 | name in abstract: TA-HPV |
| PMID 15623547 | Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. | International immunology | 2005 | name in abstract: TA-HPV |
| PMID 14522932 | Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. | Cancer research | 2003 | name in abstract: TA-HPV |
| PMID 12473576 | Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2002 | name in title: TA-HPV |
| PMID 11257391 | Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. | Vaccine | 2001 | name in abstract: TA-HPV |
| PMID 11395199 | Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. | Vaccine | 2001 | name in abstract: TA-HPV |
| PMID 11804273 | Technology evaluation: T-cell activator, Xenova. | Current opinion in molecular therapeutics | 2001 | name in abstract: TA-HPV |
| PMID 9014288 | Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. | Vaccine | 1996 | name in abstract: TA-HPV |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| P50CA098252 | Therapeutic HPV vaccines (PVX7) for Advanced Cervical Cancer | JOHNS HOPKINS UNIVERSITY | WU, TZYY-CHOOU | 2014–2026 | name in abstract: TA-HPV |
| R01CA142691 | Mechanisms of mucosal immune evasion in high grade cervical dysplasia | JOHNS HOPKINS UNIVERSITY | TRIMBLE, CORNELIA L | 2010–2014 | name in abstract: TA-HPV |
| R43CA174436 | Therapeutic vaccination against genital HPV infection | PAPIVAX, LLC | CHANG, YUNG-NIEN | 2013–2013 | name in abstract: TA-HPV |
| Z01SC010075 | A PHASE I/II STUDY OF A VACCINIA-HPV RECOMBINANT | DIVISION OF CLINICAL SCIENCES - NCI | KHLEIF, SAMIR | 1996–2000 | name in abstract: TA-HPV |
Notes
Recombinant vaccinia virus encoding HPV-16 and HPV-18 E6 and E7; used in therapeutic trials for cervical and vulval intraepithelial neoplasia since the 1990s and still used as a boost after DNA priming (e.g. the PVX7/pBI-11 regimen, NCIt C212077). Vaccinia strain (Wyeth) and the Cantab/Xenova originator attribution were not verified from a primary source in this pass; replication competence recorded as replicating on that basis and should be checked.
How to cite
TA-HPV (AXP000190.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000190.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.